Key result
Sacubitril/valsartan improved left ventricular ejection fraction and attenuated progressive left ventricular dilation compared to vehicle in rats with heart failure post-myocardial infarction.
Why the study?
ARNi therapy improves prognosis in heart failure patients, but the underlying mechanisms remain unclear.
Does sacubitril/valsartan improve myocardial remodeling and cardiac perfusion in a rat model of heart failure post-MI compared to valsartan or vehicle?
Does sacubitril/valsartan improve myocardial remodeling and cardiac perfusion in a rat model of heart failure post-MI compared to valsartan or vehicle?
Answers are grounded in this paper and cite their sources.
In a rat model of heart failure post-MI, sacubitril/valsartan improved global LV function, limited remodeling, and increased infarct perfusion more consistently than valsartan alone.
Angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy improves the prognosis of heart failure patients. However, the mechanisms remain unclear. This study investigated the biological effects of ARNi with neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan on myocardial remodeling and cardiac perfusion in experimental heart failure (HF) after myocardial infarction (MI). Male Lewis rats (10-weeks old) with confirmed HF were randomized one-week post-MI to treatment with vehicle (water), sacubitril/valsartan or valsartan, as comparator group, for either 1 or 5 weeks. Sacubitril/valsartan for 1-week limited LV contractile dysfunction vs. vehicle and both sacubitril/valsartan and valsartan attenuated progressive LV dilation after 1 and 5 weeks treatment. After 5 weeks, both sacubitril/valsartan and valsartan reduced CTGF expression in the remote myocardium, although only sacubitril/valsartan prevented interstitial fibrosis. In the border zone, sacubitril/valsartan and valsartan reduced hypertrophic markers, but only sacubitril/valsartan reduced cardiomyocyte size and increased VEGFA expression. In the infarct, sacubitril/valsartan induced an early uptake of 99mTc-NC100692 (a radiotracer of angiogenesis) and improved perfusion, as determined by 201Tl microSPECT/CT imaging. In conclusion, ARNi improved global LV function, limited remodeling in the remote and border zones, and increased perfusion to the infarct. Sacubitril/valsartan had more consistent effects than valsartan on LV remodeling in experimental HF.
No takes yet. Share an insight, caveat, or question.
Pfau et al. (2019) studied Heart failure post-myocardial infarction (n=90). Sacubitril/valsartan vs. Vehicle (water) and Valsartan (31 mg/kg/day) was evaluated on Left ventricular ejection fraction (LVEF) at 1 week after treatment (p=<0.05). Sacubitril/valsartan improved left ventricular ejection fraction and attenuated progressive left ventricular dilation compared to vehicle in rats with heart failure post-myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: